EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice

Christina T Saed iD, Seyed Amirhossein Tabatabaei Dakhili, Amanda A Greenwell, Jordan S F Chan, Kunyan Yang, Keshav Gopal, Farah Eaton, Rami Al Batran, John R Ussher iD

Basic & Clinical Pharmacology & Toxicology · 2023

DOI: 10.1111/bcpt.13906 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Christina T Saed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Canadian Liver Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Recent studies have demonstrated that stimulating pyruvate dehydrogenase (PDH, gene Pdha1 ), the rate‐limiting enzyme of glucose oxidation, can reverse obesity‐induced non‐alcoholic fatty liver disease (NAFLD), which can be achieved via treatment with the antianginal ranolazine. Accordingly, our aim was to determine whether ranolazine's ability to mitigate obesity‐induced NAFLD and hyperglycaemia requires increases in hepatic PDH activity.

Methods

We generated liver‐specific PDH‐deficient ( Pdha1 Liver−/− ) mice, which were provided a high‐fat diet for 12 weeks to induce obesity. Pdha1 Liver−/− mice and their albumin‐Cre (Alb Cre ) littermates were randomized to treatment with either vehicle control or ranolazine (50 mg/kg) once daily via oral gavage during the final 5 weeks, following which we assessed glucose and pyruvate tolerance.

Results

Pdha1 Liver−/− mice exhibited no overt phenotypic differences (e.g. adiposity, glucose tolerance) when compared to their Alb Cre littermates. Of interest, ranolazine treatment improved glucose tolerance and mildly reduced hepatic triacylglycerol content in obese Alb Cre mice but not in obese Pdha1 Liver−/− mice. The latter was independent of changes in hepatic mRNA expression of genes involved in regulating lipogenesis.

Conclusions

Liver‐specific PDH deficiency is insufficient to promote an NAFLD phenotype. Nonetheless, hepatic PDH activity partially contributes to how the antianginal ranolazine improves glucose tolerance and alleviates hepatic steatosis in obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAnimalsMaleMiceDiet, High-FatGlucoseLiverMice, Inbred C57BLMice, ObeseObesityOxidoreductasesRanolazine

Stichwörter der Autor:innen

hepatic steatosisnon-alcoholic fatty liver diseaseobesitypyruvate dehydrogenaseranolazine

Substanzen

GlucoseOxidoreductasesRanolazine

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
  • Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Faculty of Pharmacy, Université de Montréal, Quebec, Canada.

ORCID-Profile: Christina T Saed, John R Ussher

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Canadian Liver Foundation

Zitieren

APA

Saed, C. T., Tabatabaei Dakhili, S. A., Greenwell, A. A., Chan, J. S. F., Yang, K., Gopal, K., Eaton, F., Al Batran, R., & Ussher, J. R. (2023). The antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13906

Vancouver

Saed CT, Tabatabaei Dakhili SA, Greenwell AA, Chan JSF, Yang K, Gopal K, et al. The antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13906

BibTeX
@article{Saed2023,
  author = {Saed, Christina T and Tabatabaei Dakhili, Seyed Amirhossein and Greenwell, Amanda A and Chan, Jordan S F and Yang, Kunyan and Gopal, Keshav and Eaton, Farah and Al Batran, Rami and Ussher, John R},
  title = {The antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2023},
  doi = {10.1111/bcpt.13906}
}
Kostenlos starten →